Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter (AF/AFL) Recurrence in Subjects Post-Conversion Form AF

NCT00267930 is registered in ClinicalTrials.gov with Advanz Pharma as lead sponsor.

NCT NCT00267930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00267930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter (AF/AFL) Recurrence in Subjects Post-Conversion Form AF
Lead sponsor
Advanz Pharma
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2005
Completion date
August 31, 2006
Enrollment
221 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation